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Objective: To assess the effectiveness of a single daily dose of sparfloxacin in comparison with standard antibacterial 
therapy for the treatment of pneumococcal bacteremic community-acquired pneumonia (CAP). 
Methods: The results were analyzed of four comparative trials in CAP, in which 107 adult patients with CAP confirmed 
by blood cultures positive for Streptococcus pneumoniae were included. Sparfloxacin was given at a loading dose of 
400 mg followed by 200 mg daily. Comparator drugs included amoxycillin 3 g/day, amoxycillin/clavulanate 1.5/0.375 
g/day and erythromycin 2 g/day. Dosing was for 7-14 days (mean 10 days). Success was determined by a combination 
of clinical and microbiological assessment and radiologic changes. 
Results: Sparfloxacin was as effective as the comparator drugs, with an overall success rate of 80% at the end of 
treatment (comparators 78%), and a 79% success rate at follow-up (76% for comparators). There were no pneumococcal 
isolates resistant to sparfloxacin, but eight of 56 were either resistant (four) or had reduced susceptibility to penicillin 
G, and two strains were resistant to erythromycin. Tolerance to sparfloxacin was good, with fewer patients reporting 
drug-related adverse events (15.8%) than with the comparator drugs (33.3%). 
Conclusions: This analysis suggests that sparfloxacin would be an alternative candidate for empirical therapy in 
moderately severe CAP. 
Key words: Sparfloxacin, arnoxycillin, amoxycillin/clavulanate, erythromycin, Streptococcus pneumoniae, resistance, 
community-acquired, bacteremic pneumonia 
INTRODUCTION 
Community-acquired respiratory tract infections 
(RTIs) are a major cause of morbidity worldwide, and 
most require empirical therapy, since they can be acute, 
of rapid onset, and serious [l]. Community-acquired 
pneumonia (CAP) is the most serious of the respiratory 
infections, frequently requiring hospitalization and 
carrying a 5-15% mortality rate. Empirical therapy is 
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therefore generally regarded as essential [2]. Although 
traditionally the penicillins have been the mainstay of 
treatment for many CAPS, recent years have seen a 
shift towards a greater use of compounds with a 
broader spectrum of activity. A number of factors 
have contributed towards this, including: the increasing 
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numbers of B-lactamase-producing strains of Haenlo- 
pliifzis inpuenzae, Movaxella catnrrhalis and Staphylococcus 
nrrreus; the growing threat of strains of Streptococcus 
yricirrnorziae with reduced susceptibility or resistance to 
penicillin; and the recognition of the contribution 
to the pathogenesis of KTI by ‘atypical’ pathogens such 
as Clzlariiydia ptiectrnoriiae, Legionella pnectmophila and 
Mjxopla.~ri~a priecrmoriiac. 
The iiiore recent quinolones have a spectrum of 
activity that includes most of the major pathogens 
involved in RTI. However, a drawback to the empirical 
use of some of these compounds (such as ciprofloxacin 
and ofloxacin) for KTI is their limited activity relative 
to penicillins against Streptococcus ptieurnoniae [3],  still 
the most prevalent and most serious bacterial pathogen 
in CAP [1,4]. The new quinolone sparfloxacin, a 
derivative of pyridone carboxylic acid, has better 
activity than other marketed quinolones against 
Streptococcus przeumouiar [5], with M I C ~ O  values of 
0.25-0.5 nig/L [6,7]. I t  retains activity against strains 
with resistance to or decreased susceptibility to 
penicillins and niacrolides [8,9], and this good activity 
in vitro has been confirmed experimentally in vivo, 
using a mouse niodel of pneumonia [lo]. 
The activity of sparfloxacin has also been demon- 
strated in the clinic against various types of RTI, 
including CAP [11-141, and its safety in these trials has 
been summarized by Rubinstein [15]. When an oral 
loading dose of 400 mg is given, followed by a daily 
dose of 200 mg, steady state with a peak serum 
concentration of 1.4 mg/L is reached after the second 
dose. The trough concentration is 0.3 mg/L and 
the TI’? is approximately 20 h [16]. The compound 
penetrates respiratory tract tissues to a greater extent 
than other quinolones [ 3 71, achieving concentrations 
that exceed the plasma levels considerably; levels can 
thus be achieved at infective sites that exceed the 
MIC for many pathogens for prolonged periods. 
These pharmacokinetic characteristics allow once- 
daily dosing with sparfloxacin. 
Clinical trials of CAP have varied widely in their 
approach, with respect to both defining and diagnosing 
pneumonia [ 181 and assessing the efficacy of antibiotics 
112,191. Many trials assess efficacy as cure, improvement 
or failure, but the classification of ‘improvement’ is 
difficult, since it is highly subjective and does not reflect 
normal clinical practice. In the study reported here, we 
have used a simple binary expression of cure or failure 
for overall assessment (this approach is explained in 
detail by Genevois et a1 [19]). In this analysis, we 
present results on the use of sparfloxacin in the 
treatment of CAP where the infection had been 
confirmed by blood culture as having been caused 
by Streptococcus pneumoriiae. The patients were selected 
from four comparative trials in 11 countries (Europe, 
Israel and South Africa) carried out between 1990 and 
1993. Various comparator drugs were used. 
METHODS 
Study design 
The analysis was perforined on four double-blind, 
randomized, multicenter trials of CAP involving a total 
of 1654 patients. The trials were conducted mostly 
in Europe (Finland, France, Germany, Greece, The 
Netherlands, Norway, Spain, Sweden and Switzerland), 
with a few patients being recruited from Israel and 
South Africa, and the results of those individual clinical 
trials have been published elsewhere [I  1-14]. Only 
those patients with Streptococcus pneurno~iae pneumonia 
confirmed by blood culture have been included in the 
present assessment. 
Patients 
Patients of either sex, aged over 18 years, with acute 
CAP were included. Pneumonia was defined as the 
presence of typical respiratory signs and symptoms 
(including purulent bronchial or pulnionary secretions, 
cough, chills, dyspnea, sputum production, chest pain), 
a temperature equal to or exceeding 38”C, and new 
infiltrates (solid or p’tchy) evident on chest radiographs. 
Patients with severe underlying diseases (such as 
cancer, tuberculosis or AIDS, although HIV-positive 
non-AIDS patients were included), severe infections 
requiring parented or intensive care therapy (such as 
infections associated with acute respiratory distress 
syndrome, meningitis, septic shock, mechanical ventila- 
tion, or intensive bilateral consolidation on radio- 
graphs), and those with large pleural effusions on 
radiographs were excluded. Other exclusion criteria 
included treatment with systemic corticosteroids, 
antacids and iron salts, and pregnancy or lactation. 
Patients who had been hospitalized immediately before 
the onset of this episode of CAP were also excluded to 
avoid the possibility of their pneumonia being acquired 
in hospital. All patients gave their informed consent 
before entry to the study. 
Study drugs 
Patients in these trials were randomized to receive oral 
treatment with either sparfloxacin or a control anti- 
biotic. A loading dose of 400 mg of sparfloxacin 
(Rh6ne DPC, Paris, France) was given on day 1, 
followed by a daily dose of 200 mg for 7-14 days, with 
a mean value of 10 days. The comparator antibiotics 
were also administered for 7-14 days, with a mean 
value of 10 clays, and were: amoxycillin (SmithUne 
Beecham Laboratories, France). 1 g three times a 
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day; amoxycdin/clavulanate (Smithmine Beecham 
Laboratories, France), 5001125 mg three times a day; 
amoxycillin 1 g three times a day plus ofloxacin 
(Koussel Uclaf, France) 200 mg twice a day; 
roxithromycin (Roussel Laboratories, Denmark) 150 
mg twice a day; and erythromycin (August Wolff 
Laboratories, Germany), 1 g twice a day. Patients were 
advised to avoid exposure to sunlight or to tanning 
(W) lamps for the duration of the trial. 
Study conduct 
Patients in the trials were treated on an inpatient or 
an outpatient basis as convenient, but most were 
inpatients. Patients were seen on admission (visit l), 
after 48 h of treatment (i.e. at  3 days, or visit 2 ) ,  at the 
completion of (or soon after the completion 00 
treatment (visit 3) and at a follow-up visit 4-6 weeks 
after the end of treatment (visit 4). 
At visit 1, the patient’s medical and surgical history 
was noted, and blood samples collected for biochemical 
and hematologic analysis. A complete physical examina- 
tion, including temperature, respiratory rate, and 
determination of the clinical signs and symptoms of 
respiratory infection (as noted above), was performed 
at each visit. These symptoms were classified as mild, 
moderate or severe, and sputum as none, mucoid, 
mucopurulent, purulent or hemoptysis. A chest 
radiograph was taken on admission and at the follow- 
up visit. If the investigator thought it necessary, a 
radiograph was taken at the end of treatment (visit 3), 
and if this showed resolution or improvement, the 
radiograph at follow-up was not taken. Blood and 
urine samples were collected for hematologic and 
biochemical analysis at the end of treatment. If any 
abnormalities were evident in these samples, a further 
sample was taken at the follow-up visit. Additional 
blood samples for microbiological culture were taken 
only from those patients who did not respond to 
treatment. 
Patients were withdrawn from the study if protocol 
violations occurred, or if deemed necessary because of 
an adverse event, or if they failed to respond to 
treatment. Any patients discontinuing the study were 
examined at a follow-up visit. 
Analysis of efficacy 
Efficacy analyses were performed on both the intention- 
to-treat population and the evaluable population at two 
intervals; from study entry (visit 1) to end of treatment 
(visit 3) and from study entry (visit 1) to follow-up 
(visit 4). An overall efficacy classification was used that 
combined both clinical and radiologic changes and was 
expressed simply as ‘success’ or ‘failure’ [ll-14,191. 
This classification was determined by the application of 
predefined criteria. An external steering committee 
reviewed the patients when the data were contradictory 
Clinical effects were classified as cure, improve- 
ment or failure using the predetermined criteria. Cure 
included the absence of fever, chills, chest pains, cough 
or dyspnea, and the absence of sputum production at 
the follow-up visit. However, patients with cardiac 
failure, with concomitant bronchopulmonary disease, 
or who smoked, and who showed persistence of 
mild chest pain, cough, dyspnea, or the presence of 
non-purulent sputum, could stdl be classified as cured 
provided the symptoms were no worse than before the 
onset of acute illness. Improvement was classified as the 
absence of chills and fever, but other symptoms could 
be present at a predetermined level of severity. All other 
patients were classified as failures. Radiologic changes 
were classified directly by the investigators as worse, no 
change, improvement or resolution. 
Overall success was defined as those with resolution 
or improvement on X-ray examination together with 
a clinical cure, or resolution on X-ray examination 
together with a clinical improvement. All clinical 
failures, irrespective of radiologic findings, were classi- 
fied as overall failures. Those patients with conflicting 
radiologic or clinical data at visit 3 were defined by the 
steering committee at visit 4. All other patients were 
deemed overall failures. 
~ 9 1 .  
Microbiological assessment 
All patients included in this analysis were those in 
whom Streptococcus pneurnoniae had been cultured 
from the blood sample collected prior to commencing 
treatment. Wherever possible, blood samples were 
cultured from any patients not responding to treatment. 
The minimum inhbitory concentrations (MICs) for a 
range of antibiotics against the pneumococcal strains 
isolated were determined using a standard microtiter 
technique. 
Safety evaluation 
Blood samples collected immediately prior to treat- 
ment (visit 1) and at the end of treatment (visit 3) were 
analyzed for the usual biochemical and hematologic 
parameters. The urine samples were tested for protein, 
blood and glucose using a dipstick method. All adverse 
experiences, elicited by non-specific questioning or 
volunteered by the patients, were noted at each visit. 
These were classified by the investigator as mild, 
moderate, or severe/life-threatening, and their relation- 
ship to the drug administered was classified as un- 
related, possibly related, or probably related. The 
international COSTART terms were used to describe 
adverse events. 
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Statistical analysis 
All analyses, including clinical and microbiological, 
were descriptive. Overall success rates are presented for 
each group at the end of treatment and follow-up, in 
both the intention-to-treat population and evaluable 
patients. The bacteriologic response is presented in 
the clinically and bacteriologically evaluable patients. 
All patients with a premature withdrawal of the 
treatment because of an adverse event, whose consent 
was withdrawn, or who were lost to follow-up, were 
classified automatically as a failure in the intention-to- 
treat analysis, but were excluded from other efficacy 
analyses in the evaluable population. 
RESULTS 
Patients 
One hundred and seven patients with Streptococcus 
prieuvnoriiae pneumonia confirmed by blood culture 
were included in this assessment. Fifty-eight patients 
had been randomized to receive sparfloxacin and 49 
to receive one of the comparator antibiotics. In the 
comparator groups, erythromycin had been admini- 
stered to 17 patients, amoxycillin to 19, amoxycillin/ 
clavulanate to seven, amoxycillin plus ofloxacin to 
three, and roxithromycin to three. 
Of the 107 patients included in the analysis, 94 
were deemed evaluable for efficacy, and 13 patients (six 
in the sparfloxacin group and seven in the comparator 
group) were not considered to be evaluable for a 
number of reasons (listed in Table I) ,  including various 
protocol violations and the occurrence of adverse 
events. A further two patients (one in each group) were 
not evaluable at the end of treatment, and seven more 
patients (four in the spadoxacin group and three in the 
comparator group) were not evaluable at follow-up, 
leaving a total of 85 patients evaluable after the follow- 
up visit. 
Baseline data 
The demographic data for the two groups (sparfloxacin 
and comparator antibiotics) are detailed in Table 2. 
The mean age of the patients was 49 years, they were 
predominantly male, and approximately 90% were 
Caucasian. No statistically significant differences were 
evident between the two groups, although sputum 
production was more frequent in the comparator group 
(79.6%) than in the sparfloxacin group (65.5%), as was 
an association with chronic bronchitis (18.4% versus 
10.3%). 
The chest radiographs revealed an alveolar type of 
lobar pneumonia in over 95% of the cases. A single- 
lobe alveolar image was present in approximatelv 40% 
of the patients and more extensive alveolar images 
(more than one lobe, uni- or bilateral extension) were 
present in 50-60% of the patients (Table 3). 
The MIC distribution for various antibiotics against 
the strains of Streptococcus pneurnoniae isolated is detailed 
in Table 4, and shows that spadoxacin MIC values 
Table 1 Patients evaluable for efficacy and tafety 
Sparfloxacin Coinparators Total 
Patients entering study 
Patients evaluable for safety and efficacy 
Not evaluable for overall efficacy 
Intention-to-treat analysis 
No pneumonia 
Treated < 3  days 
Pulinonary e d e m ~  
CXhcr antibiotics 
N o  risk Extors 
Early withdrawal, adverse event 
Evaluable for overall efficacy 
Not evaluable at end of treatnient (visit 3) 
<hicurrent  illness 
Missing data 
Evaluable at end of treatment (visit 3)  
58 
58 
6 
1 
I' 
7 - 
2 b  
52 
1 
1 
51 
49 
49 
-, 
1 
1 '  
- 
41 
107 
107 
13 
2 
4 
1 
2 
2 
2 
94 
2 
1 
1 
92 
Not evaluable for follow-up (visit 4) 1 3 7 
Lost to follow-up - 2 4 
Other inedication 1 1 
Concurrent illness - 2 
Evaluable at follow-up (visit 4) 47 38 85 
3 
- 
7 - 
'Patient wrongly included with a mildly febrile pulmonary edema from cardiac insufficiency. 'Vomiting. 'Kenal failure. 
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were 1 mg/L or below for all except one strain, 
for which the MIC was 2mg/L. The MICYo was 
0.5 mg/L, and 59 of 67 strains (88%) were inhibited by 
0.25 mg/L. Although penicillin G, amoxycillin and 
amoxycillin/clavulanate had good activity against the 
majority of the strains tested (MIC90 0.25, 0.5 and 
0.25 mg/L), 8 of 56 (penicillin G), 10 of 61 
(amoxycillin) and 8 of 59 (amoxycillin/clavulanate) 
strains showed reduced susceptibility to the penicillins, 
MIC values ranging between 0.125 and 2 mg/L. The 
majority of strains were sensitive to erythromycin, but 
Table 2 Demographic and baseline data of patients on 
admission 
Treatment 
Sparfloxacin Comparators 
Parameter (n=58) (n=49) 
Age in years; mean (SEM) 49 (2) 49 (3) 
Males (%) 63.8 67.3 
Temperature (“C); mean (SEM) 39.4 (0.09) 39.3 (0.12) 
Chills (“h) 74.1 19.6 
Respiratory rate (min); mean (SEM) 24.1 (0.8) 25.6 (0.9) 
Dyspnea (%) 74.1 77.6 
Chest pain (“A) 82.8 89.8 
Sputum production (%) 65.5 79.6 
Associated chronic bronchitis (94) 10.3 18.4 
Associated asthma (“A) 6.9 8.2 
Pleural e l h i o n  (“h) 10.3 6.1 
Unilateral pneumonia (X-ray) (“h) 91.4 93.9 
~~~ ~~~ ~ 
Table 3 Rahologic findings of patients on admission 
Spadoxacm Comparators 
(ri=58) (n=49) 
Interstitial 2 (3.4%) 2 (4.1%) 
Alveolar-btlateral 3 (5.2%) 1 (2%) 
Alveolar-undated 25 (43.1%) 30 (61.2%) 
Alveolar-one lobe 28 (48.3%) 16 (32.7%) 
two strains were resistant, the MICs against them being 
8 and 32 mg/L. In addition, one other strain showed 
decreased susceptibility to erythromycin, only being 
inhibited by 1 mg/L. Only seven strains were tested for 
sensitivity to roxithromycin, and all were susceptible to 
0.25 mg/L or less. Ofloxacin was tested against only 
two strains; the MICs were 1.0 and 2.0 mg/L. 
Analysis of efficacy 
Overall success rates in the evaluable populations were 
similar in both the spadoxacin (80%) and the com- 
parator groups (78%) at the end of treatment, dropping 
only slightly a t  the follow-up to 79% for sparfloxacin 
and 76% for the comparators. The values for the 
intention-to-treat populations were marginally lower, 
at approximately 74% for both groups at  the end of 
treatment and 69% a t  follow-up (Table 5). 
There were three early failures in both the 
sparfloxacin group (failure on day 3) and the 
comparator group (failure at 3-4 days). All three 
sparfloxacin patients still had an elevated temperature 
(38-38.4 “C), two had mucopurulent sputum, and the 
radiographs were either no better or worse than at the 
time of entry. The Streptococcus pneumoniue strains were 
all sensitive to sparfloxacin (MICs 0.125-0.5 mg/L). In 
one patient the strain was eradicated, but in the other 
two the outcome was unknown, as no blood cultures 
were performed at the end of treatment. An assay of the 
sparfloxacin serum concentration was performed in 
two of these patients: in one patient the concentration 
was 0.4 mg/L just before drug administration (i.e. a 
trough level), and in the other 0.02 mg/L 1 h after drug 
administration. 
There were seven other failures in the evaluable 
sparfloxacin group, and these presented a variable 
picture. One patient with worsening radiographs was 
suspected of having a fungal infection and was given 
fluconazole, while another patient had persistently 
mucopurulent sputum. The other five patients had 
either a persistent fever or radiographs that did not 
Table 4 Distribution of MICs of antibiotics against Streptococcus pneurnoniae (g/L) 
0.008 0.015 0.03 0.06 0.125 0.25 0.5 1.0 2.0 4.0 8.0 32 ICso 
28 4 3 1 0 0  - 0.5 Sparlloxacin (67) 4 1 1 4 21 
Penicillin G (56) - - 43 5 2 1 1 2 2 0 0 0 0.25 
AmoxycilIin (61) - - - 51 1 2 2 3 2 0 0.5 
clavulanate (59) - - - 51 1 2 2 1 2 0 0  0 0.25 
0 0  
Amoxycillin/ 
Erythromycin (61) - 11 15 19 17 3 0 2 0 1 0.25 0 1  
- Koxithromycin (7) - - 1 1 3 2 0 0 0 0 0  0 
1 1 0 0  - Ofloxacin (2) 0 0 0 0 0 0 0 - 
-, denotes no test performed at that concentration; 0, denotes no strain with that MIC value 
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Table 5 Overall efficacy at end of treatment and at follow- 
up; intention-to-treat and evaluable population 
Spadoxacin Comparators 
No. of patients in study 
Intention-to-treat: 
end of treatment 
Succes 
Fail ui-e 
Early failure 
Intention-to-treat: follow-up 
Success 
Failure 
Early failure 
Evaluable: end of treatment 
succr\s 
Failurc 
Early hilure 
Evaluable; follow-up 
SucceSF 
Failurc 
Early failure 
58 
58 
43 (74.1%) 
12 (20.7%) 
3 (5.2%) 
10 (69%)) 
3 (5.2%) 
11 (8n.4o/o) 
3 (5.9%) 
37 (78.7%) 
3 (6.4%)) 
58 
15 (25.9%)) 
51 
7 (13.7%) 
47 
7 (14.9%) 
49 
49 
36 (73.5%) 
10 (20%) 
3 (6.1%) 
49 
34 (69.%) 
3 (6.1) 
12 (24.5) 
41 
32 (78%)) 
6 (14.6'%) 
3 (7.3) 
38 
29 (76.3%) 
6 (15.8%) 
3 (7.9%) 
improve. All isolates from these patients were sensitive 
to sparfloxacin. 
111 the comparator group, one early failure was 
treated with erythromycin and two with amoxycillin. 
All three had temperatures of 39°C or inore and 
radiographs that had either deteriorated or not im- 
proved. The patient treated with erythromycin was 
infected with a strain of pneumococcus that was 
resistant to erythromycin (MIC 32 nig/L); a sub- 
sequent culture was not obtained. 
There were six other failures in the evaluated 
patients treated with comparators, three with erythro- 
mycin and three with amoxycillin/clavulanate. Three 
patients failed at 5-6 days with fever and non- 
improving radiographs; in addition, one of these 
patients had a persistent cough and dyspnea. The other 
Table 6 Microbiological assessment; isolation of 
Streptococcus pnrurnoniae 
End of treatment Follow-up (visit 4) 
Spar- Com- 
floxacin parator 
Eradication 5 3 
Presumed eradication 38 3 0 
Persistence 2 h  
Negative culture 1 2 
Nan-evaluable 14 1u 
- 
Spar- Coiii- 
floxacin paratot 
1 1 
37 31 
- 1' 
1 d 
20 15 
~ 
"A negative culture but a clinical failure. 
"Persistent positive blood culture a t  end of treatiiient. 
'Clinical relapse with positive blood culture after end of treatment 
in an HIV-positive patient. 
dClinical failure with negative culture at end of treatment. but not 
evaluable at follow-up 
three patients continued to have a slight fever and/or 
chest pain, although chest radiographs were improved. 
In one patient treated with erythromycin, the pneumo- 
coccal strain was resistant to erythroniycin (MIC 
8 ing/L). 
Microbiological response 
Although the protocol specified that d blood sample 
should be collected from patients in whom treatment 
was not a success, for many patients no follow-up 
sample was obtained; the number of non-evaluable 
responses was therefore high. If, however, the patient 
was classified as a success, then it was presumed that the 
organism was eradicated. Table 6 lists the micro- 
biological responses to the therapy at the end of 
treatment and at follow-up. 
There were no patients with a persistent infection 
in the sparfloxacin group. In one patient treated with 
erythromycin, the blood culture was still positive after 
2 days of treatment; the patient was withdrawn from 
the study and treated with other antibiotics. Another 
patient who was HIV positive and treated with 
Table 7 Summary of advcrse events 
Spadoxacin <kinparators 
Total nuniber of patients 57 48 
Number stopping therapy 5 .) 3'' 
Total number of advrrse evcnts reported 
Number of pdtierits reporting adverse evcnts 
"/o of patirnts rcporting adversc cveuts 
49 
32 
5 6 
h0 
31 
64 h 
Number of drug-relatcd adverse events 1s 17 
Number of patients reporting drug-related adverse evcnts 9 1 6 
%I of patients reporting drug-related adverse events 15.8 33.3 
'Vomiting in two patients, clinical sign5 of failure in three patients. 
"clinical signs of failure. 
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erythromycin relapsed after the end of treatment with 
meningitis and had a blood culture positive for Strepto- 
coccus pneumoniae. A patient treated with amoxycillin/ 
clavulanate had a persistent bacteremia after 5 days of 
treatment, although responding clinically and radio- 
logically. 
Eight strains of Streptococcus pneumoniae had reduced 
susceptibility to or were resistant to penicillin G and 
amoxycillin (MICs 0.125-2.0 mg/L) and two strains 
were resistant to erythromycin (MICs 8 and 32 mg/L). 
One of the erythromycin-resistant strains also had 
reduced susceptibility to penicillin (MIC 0.5 mg/L). 
Both of the patients infected with the erythromycin- 
resistant strains were randomized to receive erythro- 
mycin, and failed treatment. Of the four patients 
infected with penicillin-resistant pneumococci (MIC 
1 .O and 2.0 mg/L), three received sparfloxacin and 
one erythromycin; all four responded successfully to 
therapy. Three patients infected with pneumococci 
with reduced penicillin susceptibility (MICs 0.125- 
0.25 mg/L) were treated successfully, two with erythro- 
mycin and one with amoxycillin. 
Safety evaluation 
Overall, the incidence of adverse events reported was 
similar in both groups, with a total of 32 patients in the 
sparfloxacin group reporting 49 adverse events, and 
31 patients in the comparator group reporting 60 
adverse events. Of  these adverse events, only 15 in the 
sparfloxacin group were regarded as being possibly or 
probably related to the drug compared with 17 events 
in the comparator group. Fewer patients reported 
drug-related adverse events in the sparfloxacin group 
(15.8%) compared with the comparator drugs (33.3%) 
(Table 7). There were slightly more gastrointestinal 
disturbances reported by patients receiving comparator 
drugs, and slightly more skin-related events in patients 
receiving sparfloxacin, but none of these were reports 
of phototoxicity. 
Three patients suffered severe or life-threatening 
adverse events that were regarded by the investigator 
as probably related to the treatment. One elderly 
male patient receiving sparfloxacin had severe nausea, 
vomiting and weight loss; the drug was withdrawn and 
he recovered uneventfully. The other two patients both 
had severe or life-threatening pneumonia; one was 
receiving erythromycin and one sparfloxacin. Both 
drugs were discontinued. Two patients died of causes 
unrelated to their therapy. One HIV-positive non- 
AIDS patient receiving erythromycin, after responding 
to therapy, relapsed and died of meningitis, and one 
chronic bronchitic patient with emphysema who 
received sparfloxacin died of respiratory failure and 
pulmonary aspergillosis. 
DISCUSSION 
The patients in the study reported here all had well- 
documented CAP with blood cultures positive for 
Streptococcus pneumoniae, and the severity of the disease 
in the two treatment groups was similar at  baseline. 
Sparfloxacin at  a single oral daily dose of only 200 mg 
produced a success rate that was at  least equal to that 
seen with the comparator drugs; amoxycillin 3 g/day, 
amoxycillin plus ofloxacin (3 g plus 400 mg/day), 
amoxycillin/clavulanate 1.510.375 g/day, erythromycin 
2 g/day or roxithromycin 300 mg/day. In the evaluable 
patients the success rate was 80% for sparfloxacin versus 
78% for the comparators, and in the intention-to-treat 
population it was 74% for sparfloxacin versus 73.5% for 
the comparators at the end of treatment. 
Since CAP can be such a serious disease, progress- 
ing rapidly if not treated immediately, and since 
Streptococcus pneumoniae is still an important and major 
pathogen [I], it is essential that the antibacterial agent 
given has good activity against the pneumococcus. 
Although penicillins have proved the mainstay of 
therapy against Streptococcus pneumoniae for decades, 
the increasing occurrence of strains with reduced 
susceptibility or resistance to penicillin worldwide 
[20] has compromised their value. The incidence of 
resistance varies between surveys and between 
countries, but Geslin and Leophonte, in a survey of 
14786 strains isolated in France between 1984 and 
1993, found an increasing incidence of penicillin 
resistance from 0.5% in 1984 to 12% in 1990 and 
25% in 1993 [21]. Resistance has also appeared to 
erythromycin [20], and in the same French survey, 
resistance to erythromycin increased from 18.9% in 
1984, to 26.2% in 1990 and 34.8% in 1993 (211. Geslin 
and Leophonte also examined 1182 invasive strains of 
Streptococcus pneumoniae (isolated from the blood), and 
again saw an increase in resistance, with 22.9% resistant 
to erythromycin and 14.8% resistant to penicillin 
in 1993 [21]. Multiresistant strains of pneumococci 
are also increasing, and these are more likely to be 
community acquired [22]. 
The doses of the comparator drugs were chosen 
to reflect current clinical practice. Amoxycillin/ 
clavulanate is widely used at 500/125 mg three times 
a day, and is frequently favored because of its cover 
of pneumococci and P-lactamase-producing strains of 
H. infuenzae and Moraxella catarrhalis. However, the 
decreasing susceptibility of the pneumococcus noted 
above has led to a high dose of amoxycillin (3 g/day) 
being favored by some. Erythromycin is generally 
given at 2 g/day for CAP, and is used for its good 
cover of the atypical pathogens as well as Streptococcus 
pneumoniae. The dose of sparlloxacin was chosen from 
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preliminary studies showing good tolerance [15] and 
desirable pharmacokinetics [16]. 
Both macrolides and quinolones have the ability to 
penetrate cells and accumulate in tissues. They also have 
good activity against most of the ‘atypical’ pathogens 
that can be involved in respiratory tract infections, and 
erythromycin has long been used as an alternative to 
penicillins. However, as noted above, the increasing 
number of macrolide-resistant strains of pneumococci 
are a cause for concern when using erythromycin. The 
quinolones currently available do not have sufficiently 
high activity against Streptococcus pneumoniae to allow 
them to be used as first-line empirical therapy [3], and 
indeed their use for this purpose has been heavily 
criticized [23]. In contrast, sparfloxacin has been shown 
to have good activity against a range of pneumococci, 
including penicillin-sensitive, penicillin-resistant, and 
multiresistant strains [S-91, whilst still retaining the 
usual broad spectrum of quinolones, which includes 
most respiratory pathogens. 
In this trial all of the pneumococcal strains tested 
were susceptible to sparfloxacin (67),  but two of 
68 were resistant to and one of 68 had reduced 
susceptibility to erythromycin. In addition, eight of 
56 strains had decreased susceptibility to penicillin, 
with four of them being resistant to penicillin (MICs 1 
and 2 nig/L). O f  the patients infected with these 
resistant strains, three were treated successfully with 
sparfloxacin and one with erythromycin. Although the 
rise in pneumococci with reduced susceptibility and 
resistance to penicillins gives cause for concern, it is 
debatable as to whether this is always reflected in a 
reduced response to penicillins in cases of moderate 
CAP, especially when the organism is of intermediate 
resistance. The evidence for a lack of response to 
penicillins in more severe infections, particularly 
meningitis, or in the immunocompromised, especially 
when caused by fully resistant strains, is better 
documented [22,24]. There are, however, claims that 
resistance to erythromycin can lead to a poor 
therapeutic outcome [22,24]; it is thus of interest to 
note that in this trial the two erythromycin-resistant 
strains were isolated from patients who were treated 
unsuccessfully with erythromycin. 
Overall, there were too few isolates resistant to 
Fparfloxacin or other agents to draw any firm con- 
clusions regarding the value of sparfloxacin, although 
these results are encouraging. The individual cases of 
early failures observed in the patients treated with 
sparfloxacin are unexplained, except possibly for one 
patient in whom the seruni level I h post-dosing was 
unusually low (approximately 0.02 mg/L). Trough 
levels of sparfloxacin following a daily dose of 200 mg 
are generally approximately 0.5 mg/L [16], so it is 
possible that the low levels of sparfloxacin in this patient 
may have been inadequate. 
Since so few serum samples were available at the 
end of treatment or at follow-up, it was difficult to 
determine in many cases whether the pneumococcus 
had been eradicated. There were, however, no cases 
of persistent bacteremia in patients treated with 
sparfloxacin, but two cases occurred in the comparator 
group, one treated with erythromycin and one with 
amoxycillin/clavulanate. In addition, one HIV patient 
in the comparator group relapsed post-therapy and was 
bacteremic at follow-up. 
Sparfloxacin was well tolerated, the number of 
patients reporting drug-related adverse events being 
less in the sparfloxacin group (15.8%) than in the 
comparator group (33.3%)). There were more gastro- 
intestinal disturbances with comparator compounds 
than with sparfloxacin. Patients were advised to avoid 
exposure to the sun, and no cases of phototoxicity were 
reported. 
In conclusion, this analysis of a subset of 
patients from four wider trials has demonstrated that 
sparfioxacin, given in a single daily dose, for an average 
of 10 days, is at least equivalent to standard antibacterial 
treatment for bacteremic pneumococcal pneumonia. 
Although some pneumococcal strains were resistant to 
penicillin or to erythromycin, all were sensitive to 
sparfloxacin. Sparfloxacin was better tolerated than the 
comparator drugs, with fewer gastrointestinal effects 
being reported. The drug’s pharmacokinetic profile 
[16], its ability to penetrate cells and accumulate in 
respiratory tissues in high concentrations [17], and 
once-daily dosing make it an alternative candidate for 
the empirical therapy of moderately severe CAP. 
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